RAN
0.005
66.7%
MGX
0.35
-25.5%
TAS
0.038
65.2%
BIT
0.003
-25%
HWK
0.04
33.3%
1AD
0.004
-20%
PKY
0.02
33.3%
TMX
0.004
-20%
WSR
0.008
33.3%
MDR
0.022
-18.5%
UNT
0.013
30%
BLU
0.005
-16.7%
ELT
0.36
28.6%
BNL
0.005
-16.7%
TAT
0.054
28.6%
CR9
0.005
-16.7%
EVG
0.032
28%
OVT
0.005
-16.7%
VHL
0.033
26.9%
VAR
0.005
-16.7%
OEL
0.005
25%
YUG
0.045
-16.7%
PIL
0.005
25%
IFG
0.011
-15.4%
VBS
0.17
21.4%
PVT
0.017
-15%
CTO
0.012
20%
RAU
0.255
-15%
SKK
0.061
19.6%
CPM
0.053
-14.5%
RBX
0.055
19.6%
EXT
0.012
-14.3%
AUR
0.02
17.6%
RDN
0.006
-14.3%
INF
0.02
17.6%
GED
0.062
-13.9%
PIM
0.2
17.6%
ATR
0.935
-13.4%
AVE
0.007
16.7%
YAR
0.013
-13.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NTI Completed patient recruitment for its clinical trial for children with Autism

Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts